Loading stock data…
INNV
$8.12+0.14 (+1.75%)
InnovAge Holding Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
InnovAge Holding Corp. in the Healthcare sector is trading at $8.12. The stock is currently 24% below its 52-week high of $10.69, remaining 36.0% above its 200-day moving average. Technical signals show neutral RSI of 45 and bullish MACD crossover, explaining why INNV maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.12
Potential Downside
89.8%
Whystock Fair Value$0.83
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Hold
Mean target$7.00-13.8%
Range$7.00 – $7.00
Fundamentals
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. It manages its business through Program of All-Inclusive Care for the El...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
153.00
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.80%
Volume
Today's trading volume
561,044
Recent News
InnovAge Q3 Earnings Call Highlights
InnovAge (NASDAQ:INNV) reported fiscal third-quarter 2026 results that management said reflected “stronger operating execution” and the benefits of investments made to strengthen its platform. The company, which operates Programs of All-Inclusive Care for the Elderly (PACE) centers, posted approxima
InnovAge Holding Corp. (INNV) Reports Q3 Loss, Beats Revenue Estimates
InnovAge (INNV) delivered earnings and revenue surprises of -488.01% and +7.46%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Can Strong Growth Aid INNV's Q3 Earnings Amid Margin Seasonality?
InnovAge heads into fiscal Q3 earnings with strong growth momentum and margin gains, but seasonal cost pressures and fading Medicaid tailwinds may temper near-term upside.
Humana Bets on Pharmacists to Lift Chronic Care Outcomes
HUM taps pharmacists via a value-based program in Ohio to boost hypertension and diabetes outcomes while aiming to curb costs and improve care access.
How The InnovAge Holding (INNV) Story Is Evolving After JPMorgan’s Updated US$7 Target
JPMorgan has lifted its price target on InnovAge Holding to US$7 from US$5, putting a new marker on where its model says the shares could reasonably trade. The firm still keeps an Underweight rating; the higher target reflects refreshed assumptions in its framework rather than a shift in stance. As you read on, you will see how this updated target fits into the broader analyst narrative and what to watch as that story develops. Stay updated as the Fair Value for InnovAge Holding shifts by...